Millions of Americans living with diabetes trusted Dexcom’s continuous glucose monitors to keep them safe. Now, a cascade of federal recalls, a landmark consolidated class action, investor fraud claims, and heartbreaking wrongful death suits are raising urgent questions about whether those devices delivered on that promise. With five overlapping class action complaints consolidated by the U.S. District Court for the Southern District of California on May 15, 2026 — captioned In re: Dexcom CGM Litigation — and the FDA’s enforcement actions mounting, anyone who used a Dexcom G6 or G7 needs to understand what is unfolding and what legal rights may be available.
What Is the Dexcom Lawsuit and Why Does It Matter in 2026?
The Dexcom lawsuit landscape encompasses several parallel legal tracks that converged dramatically in mid-2026. At its core, plaintiffs allege that Dexcom’s G6 and G7 continuous glucose monitors (CGMs) were defectively designed and manufactured, producing dangerously inaccurate blood glucose readings that failed to alert users to life-threatening hypoglycemia, hyperglycemia, diabetic ketoacidosis (DKA), seizures, coma, and death. These are not minor calibration disputes — for insulin-dependent diabetics relying on real-time CGM data to make dosing decisions, an inaccurate reading can be fatal.
The FDA’s medical device recall database documents the severity of reported failures, and the agency’s own enforcement actions against Dexcom have added significant regulatory weight to the civil litigation now moving through federal court. For patients evaluating whether they have a claim, understanding how these overlapping legal and regulatory developments connect is critical.
FDA Enforcement Actions: Warning Letters and Multiple Class I Recalls
The March 2025 FDA Warning Letter
On March 4, 2025, the FDA issued a formal warning letter to Dexcom citing deficiencies in the company’s manufacturing processes, quality management systems, and responses to prior Form 483 observations. The agency’s findings signaled that Dexcom had failed to adequately address identified manufacturing shortcomings — a regulatory red flag that plaintiff attorneys in the Dexcom lawsuit have characterized as direct evidence of systemic quality control failures. An FDA warning letter of this nature is among the agency’s most serious pre-enforcement tools, and its issuance laid important groundwork for the civil litigation that followed throughout 2025 and into 2026.
Multiple Class I Recalls Across G6 and G7 Devices
The FDA’s highest-severity recall classification — Class I, meaning a reasonable probability of serious adverse health consequences or death — was applied to Dexcom devices multiple times across 2025 and 2026. Among the most significant actions, Dexcom issued recalls covering more than 36,000 G6 receivers and over 600,000 G7 receivers worldwide. The defect involved faulty foam causing the speaker to lose contact with the circuit board, silencing critical glucose alerts that insulin-dependent patients depend on around the clock. These recalls have been linked to at least 56 documented adverse events, a figure that plaintiff attorneys argue understates the true scope of harm given widespread underreporting of medical device injuries. Additional Class I recalls followed for G7 software applications due to design errors that prevented critical sensor failure alerts from reaching users in time to take corrective action.
Taken together, the pattern of recalls — spanning hardware defects in both the G6 and G7 product lines as well as software failures — has become a centerpiece of the consolidated federal litigation. Plaintiffs argue that the volume and frequency of Class I actions, combined with the FDA’s 2025 warning letter, demonstrate that Dexcom’s quality failures were not isolated incidents but rather the product of systemic manufacturing and oversight breakdowns.
In re: Dexcom CGM Litigation: The Consolidated Federal Class Action
How the Cases Came Together
By early 2026, multiple plaintiffs across the country had filed overlapping class action complaints raising substantially similar allegations against Dexcom. On May 15, 2026, the U.S. District Court for the Southern District of California consolidated five of those complaints into a single proceeding captioned In re: Dexcom CGM Litigation. Consolidation before a single federal judge in Dexcom’s home district of San Diego is a pivotal procedural milestone — it eliminates duplicative discovery, creates a unified pretrial schedule, and positions the case for either a bellwether trial or a global settlement negotiation. The Southern District of California is no stranger to complex medical device litigation, and the assignment of these cases to a single docket signals that the court views this matter as one of significant scope and consequence.
What the Class Action Alleges
The consolidated complaints allege that Dexcom designed, manufactured, and sold G6 and G7 CGM devices that were defective and failed to perform as warranted. Specific claims include products liability on theories of design defect, manufacturing defect, and failure to warn; breach of express and implied warranty; violation of state consumer protection statutes; and unjust enrichment. Plaintiffs allege that inaccurate glucose readings caused by the recalled devices deprived users of the timely alerts they needed to prevent dangerous glycemic events. The complaints further allege that Dexcom knew or should have known of these defects and continued marketing the devices as safe and reliable while concealing known risks from patients, prescribers, and regulators. The FDA’s 2025 warning letter and the Class I recalls covering hundreds of thousands of units are cited extensively throughout the consolidated pleadings as evidence of Dexcom’s awareness of and failure to remediate systemic manufacturing problems.
Investor Securities Class Action: Fraud Allegations Against Dexcom
Parallel to the consumer class action, Dexcom faces significant exposure on a separate securities fraud front. On April 10, 2026, plaintiffs in a pending securities class action filed an amended complaint alleging that Dexcom made materially false and misleading statements regarding the accuracy, reliability, and functionality of its G7 device during a class period spanning July 2024 through September 2025. The amended complaint alleges that Dexcom executives and the company itself assured investors that the G7 met its performance benchmarks and that quality issues were being adequately managed — representations that plaintiffs contend were contradicted by the internal manufacturing deficiencies the FDA later identified in its March 2025 warning letter and by the wave of Class I recalls that followed.
Securities class actions of this type can produce substantial settlements independent of consumer litigation. They also generate significant document discovery that frequently proves useful to plaintiffs in the parallel personal injury and consumer protection cases. Investors who purchased Dexcom securities during the July 2024 to September 2025 class period and suffered losses as the company’s stock declined following disclosure of the device failures and regulatory actions may have independent claims worth evaluating with qualified securities litigation counsel.
Wrongful Death Lawsuits: The Human Cost of Alleged CGM Failures
Behind the procedural milestones and regulatory enforcement actions are individual human tragedies that give the Dexcom lawsuit its most urgent dimension. Attorneys representing families of patients who died following alleged CGM failures have filed wrongful death and survival action lawsuits alleging that inaccurate Dexcom readings — or the complete absence of alerts due to silenced speakers — directly contributed to fatal glycemic events. These individual cases, which may be coordinated with or filed separately from the class action, are among the most legally significant in terms of potential damages. Wrongful death claims can encompass economic damages including lost earning capacity and medical expenses, as well as non-economic damages for loss of companionship and, in jurisdictions that permit it, punitive damages when the conduct at issue is found to be willful or reckless.
The 56 adverse events documented in connection with the speaker malfunction recall represent the tip of a reporting iceberg. Medical device adverse event reporting to the FDA is voluntary for patients and healthcare providers, meaning actual injury numbers from device failures are routinely higher than official figures suggest. Plaintiff attorneys investigating wrongful death claims are conducting their own surveys of former Dexcom users and their families to identify additional cases that may not have been captured in FDA reporting.
Dexcom Ends G6 Production: What It Means for Litigation
Dexcom ceased manufacturing the G6 continuous glucose monitor on July 1, 2026. While the company has framed this as a planned product transition toward the G7 and next-generation devices, the timing carries significant legal implications. For plaintiffs, the end of G6 production raises immediate concerns about evidence preservation. Manufacturing records, quality control data, internal communications about known defects, and physical device components are all potentially relevant evidence that could become more difficult to obtain as production lines are decommissioned and facilities are repurposed.
Litigation counsel in In re: Dexcom CGM Litigation have been aggressive about seeking broad litigation holds to prevent spoliation of evidence related to G6 manufacturing. Courts take spoliation seriously, and a failure to preserve relevant evidence following reasonable anticipation of litigation can result in adverse inference instructions or other sanctions that significantly disadvantage a defendant at trial. For current and former G6 users who have not yet filed claims, the end of production underscores the urgency of consulting with an attorney promptly — both to preserve their own evidence and to understand how applicable statutes of limitations apply to their specific situation.
Who May Have a Dexcom Lawsuit Claim?
The populations most likely to have viable claims in the Dexcom litigation include the following categories of individuals and families:
- G6 or G7 users who suffered physical injury. Any person who used a recalled Dexcom G6 or G7 device and experienced a serious adverse health event — including hypoglycemic or hyperglycemic crisis, seizure, loss of consciousness, DKA hospitalization, or death — should consult with a mass tort attorney immediately. This is particularly true if the event occurred during a period covered by one of the Class I recalls or following the issuance of the FDA’s 2025 warning letter.
- Families of patients who died. Families who lost a loved one with diabetes and have reason to believe that a Dexcom CGM failure — including a silenced speaker alert or an inaccurate glucose reading — contributed to that death may have wrongful death claims with significant damages potential.
- G6 or G7 purchasers who did not suffer physical injury but incurred economic losses. Consumer protection and warranty claims in the consolidated class action may be available to individuals who purchased affected devices and experienced device failures, received recalled units, or paid out of pocket for devices that did not perform as advertised, even if they were fortunate enough to avoid physical harm.
- Investors who purchased Dexcom securities during the class period. Individuals or institutional investors who bought Dexcom stock between July 2024 and September 2025 and incurred losses following corrective disclosures may have securities fraud claims under the amended complaint filed April 10, 2026.
Statutes of limitations for medical device personal injury claims vary by state and typically run two to three years from the date of injury or the date the plaintiff discovered — or reasonably should have discovered — the connection between the device and the injury. Given that the consolidated litigation is now actively moving forward in federal court in San Diego, the window for joining or filing related claims is narrowing. Anyone who believes they may have a claim should seek a confidential case evaluation without delay.
Frequently Asked Questions About the Dexcom Lawsuit
What is the Dexcom lawsuit about?
The term “Dexcom lawsuit” in 2026 refers to a cluster of related legal proceedings targeting Dexcom’s G6 and G7 continuous glucose monitors. The primary consumer litigation — In re: Dexcom CGM Litigation, consolidated in the Southern District of California on May 15, 2026 — alleges that these devices were defectively manufactured and failed to deliver accurate glucose readings and reliable alerts, causing serious physical harm to insulin-dependent diabetics. Separate wrongful death lawsuits allege device failures contributed to patient deaths. A securities class action alleges that Dexcom made false and misleading statements to investors about G7 device performance between July 2024 and September 2025. All of these legal proceedings are informed by the FDA’s March 2025 warning letter and multiple Class I recalls covering more than 600,000 G7 and 36,000 G6 units.
What are the Dexcom G6 and G7 recalls?
Between 2025 and 2026, the FDA classified multiple Dexcom device recalls at the Class I level — its most serious designation, reserved for situations presenting a reasonable probability of serious adverse health consequences or death. The most significant hardware recall affected more than 600,000 G7 receivers and more than 36,000 G6 receivers due to a speaker malfunction caused by faulty foam that could prevent critical glucose alerts from sounding. This recall was linked to at least 56 reported adverse events. Additional recalls targeted G7 software applications for alert delivery failures. Consumers who received recall notices or used affected devices during the recall periods should retain all documentation and consult a qualified attorney.
Who can file a Dexcom lawsuit claim?
Individuals who used a recalled Dexcom G6 or G7 CGM and suffered a serious injury — or families of patients who died — are the strongest potential plaintiffs for personal injury and wrongful death claims. Consumers who experienced device failures and incurred economic losses without physical injury may participate in the consumer protection class action. Investors who purchased Dexcom securities between July 2024 and September 2025 and suffered losses may have securities fraud claims. Each category of claim has distinct legal requirements and deadlines, making early consultation with an attorney essential.
What is the current status of In re: Dexcom CGM Litigation?
As of mid-2026, In re: Dexcom CGM Litigation is in its early consolidated phase following the May 15, 2026 consolidation order issued by the U.S. District Court for the Southern District of California. The court is expected to appoint lead and liaison counsel for the plaintiff class, establish a pretrial scheduling order, and begin coordinating discovery. The litigation is at an inflection point — early enough that individuals with viable claims can still pursue them, but advanced enough that delay carries real risk. Settlement discussions typically intensify once discovery is underway and the court has ruled on threshold legal questions, potentially in late 2026 or 2027.
What damages can Dexcom lawsuit plaintiffs recover?
Damages available to Dexcom lawsuit plaintiffs depend on the nature and severity of their claims. Personal injury plaintiffs may seek compensation for medical expenses, lost wages, pain and suffering, and permanent disability. Wrongful death plaintiffs may seek economic damages for lost financial support and non-economic damages for loss of companionship, with punitive damages potentially available in jurisdictions that permit them where egregious corporate conduct is established. Consumer class members may recover the purchase price of recalled devices, out-of-pocket costs, and injunctive relief. Securities fraud plaintiffs may recover investment losses attributable to Dexcom’s alleged misrepresentations. No recovery is guaranteed, and outcomes will depend on the specific facts of each case and how the litigation progresses.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.